GlassScriptPhysician profile
Scott A Turner
NPI 1629093661
$3,753.66
in general payments reported to CMS, 2019-2025
29 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $244 · 2021: $123 · 2022: $322 · 2023: $410 · 2024: $1,953 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450 · Travel and Lodging: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.59 |
| Travel and Lodging | $1,330.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,330.89 | 2023-2024 | Da Vinci Surgical System |
| Lilly USA, LLC | $499.07 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $370.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $292.38 | 2022-2025 | Breztri, Farxiga |
| Abbvie INC. | $168.15 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.36 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $104.12 | 2020-2025 | Shingrix |
| Axsome Therapeutics, INC. | $89.84 | 2025 | Auvelity |
| Abbott Laboratories | $71.08 | 2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $65.02 | 2019 | |
| Phathom Pharmaceuticals, INC. | $59.24 | 2024 | Voquezna |
| Lundbeck LLC | $48.47 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $47.66 | 2022 | |
| Dexcom, INC. | $45.71 | 2021-2023 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.03 | 2022-2024 | Otezla, Repatha, Evenity |
| Pfizer INC. | $41.53 | 2021-2023 | |
| Eisai INC. | $38.37 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $37.88 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $26.72 | 2021-2023 | Seglentis, Livalo |
| Optos, INC. | $19.70 | 2020 | |
| Inspire Medical Systems, INC. | $18.73 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $15.09 | 2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Organon LLC | $14.67 | 2023 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.58 | 2024 | Caplyta |
| Grifols USA, LLC | $14.27 | 2019 | |
| Allergan, INC. | $13.93 | 2020 | |
| Exact Sciences Corporation | $12.89 | 2023 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.